title: Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.
authors.affiliation: Cochrane Institute of Public Health & Primary Care, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: C J
authors.initials: CJ
authors.lastname: Currie
authors.forename: S E
authors.initials: SE
authors.lastname: Holden
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D054795:Incretins / Q000008:administration & dosage*; D008297:Male; D008687:Metformin / Q000008:administration & dosage*; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D013453:Sulfonylurea Compounds; D008687:Metformin